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Neuromyelitis optica (NMO, Devic’s syndrome) is a demyelinating disease of the 
central nervous system that predominantly affects the spinal cord and optic nerves. 
It is often confused with multiple sclerosis. Early discrimination between NMO and 
multiple sclerosis is important because the two diseases have different natural his-
tories and treatment regimens. Seropositivity for NMO-IgG and longitudinally 
extensive spinal cord lesions (3 or more spinal segments) are characteristic of NMO. 
Despite the absence of a definitive therapeutic strategy for NMO syndrome, methyl-
prednisolone pulse therapy is recommended in the acute phase. Treatment strategies 
in relapse phases are aimed at preventing relapses, and increasing evidence shows 
a better clinical response of immunosuppressive therapy than immuno-modulating 
therapy (a standard multiple sclerosis-modulating therapy). We describe a 10-year-old 
girl who had visual loss due to acute optic neuritis at 6 years old and suffered repet-
itive myelitis 2 years later. NMO was diagnosed because of characteristic longitudinal 
myelitis and positive NMO-IgG. After combining therapy with prednisolone and an 
immunosuppressant (cyclophosphamide), the patient’s medical condition was stable 
and no relapse symptoms were observed.
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Neuromyelitis optica (NMO), also known as Devic’s 
syndrome or Devic’s disease, is an immune-mediated 
demyelinating central nervous system disease that 
pre ferentially affects the spinal cord and optic 
nerves.1−4 It is controversial whether NMO is a variant 
of multiple sclerosis (MS) or is a distinct disease. 
However, diverse sources of evidence suggest that 
NMO is distinct from MS and that the pathogenesis 
of NMO is dominated by humoral mechanisms.3,4 This 
disease is more prevalent in Black, Asian, and Indian 
populations.5,6 The current prevalence estimates 
suggest that the prevalence of NMO in Japan is ap-
proximately 14 per 1,000,000, while in northwest 
England it is approximately 4 per 1,000,000.5,6 In all 
populations there is a strong female predominance, 
with a female-to-male ratio of 3:1. The mean age 
of onset is approximately 40 years old, although many 
cases have been reported in childhood.2,3
It is important to differentiate NMO from MS early 
because NMO (especially relapsing NMO) has a more 
severe morbidity than MS and standard MS-modifying 
therapies may not be effective on NMO.1−4,6 Neuro-
myelitis optica-immunoglobulin G (NMO-IgG), an IgG 
auto-antibody binding to the aquaporin-4 (AQP4) 
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water-pump channel localized on the abluminal 
side of blood vessels and astrocytic foot processes, 
has a high sensitivity and specificity to NMO.3−5,7 
Thus, NMO-IgG has been incor porated into the up-
dated diagnostic criteria for NMO.3
We report a 10-year-old girl who presented 
with her optic neuritis (ON) at 6 years old and had 
recurrent transverse myelitis 2 years later.
2.  Case Report
A 10-year-old girl presented with unrelenting ab-
dominal cramps and general malaise. Over the 
past half year, she had experienced abdominal pain 
with intermittent acute exacerbations that re-
quired emergency department visits. There was no 
family history of autoimmune disease. Tracing back 
her medical history, it was found that she had (1) 
acute bilateral ON with a sequela of total visual loss 
since 6 years of age and (2) acute myelitis at 8 years 
of age when she complained of back pain and spinal 
magnetic resonance imaging (MRI) showed high-
signal lesions over T2−T3 and T5−T9 on T2-weighted 
images. Her back pain was relieved after treatment 
of oral prednisolone.
The major abnormalities of a physical examina-
tion on admission were a diffusely distended abdo-
men and periumbilical tenderness. Although the 
patient had malaise, she could walk independently. 
An abdominal standing X-ray revealed ileus over the 
right lower quadrant region, and an abdominal echo 
was essentially normal except for one 1.4 cm ac-
cessory spleen. Complete blood count biochemistry 
and urinary routine were within normal limits. The 
patient was taken off food and drink, and placed on 
intravenous fluids. Because of recurrent abdo minal 
cramps, a lower gastrointestinal tract series was 
arranged and it showed no evidence of organic le-
sions or inflammatory bowel disease.
Seven days after admission the patient complained 
of bilateral lower limb weakness and urinary reten-
tion was found. Muscle power was grade 4 out of 5 in 
bilateral upper limbs, and grade 3 out of 5 in bilateral 
lower limbs. Babinski sign was negative. Acute mye-
litis was highly suspected, and spinal MRI showed 
a longitudinal extensive myelitis centrally located 
within the cord from C6 to T5 (Figure 1) and overdis-
tension of the urinary bladder. To investigate the 
etiology of acute myelitis, an examination for auto-
immune disease and cerebrospinal fluid analysis 
were carried out. The patient had an increased anti-
nuclear antibody (ANA) titer of 1:640 dilution, slightly 
decreased serum complement factor C4 levels 
(9.8 mg/dL; normal range, 10−40 mg/dL), low normal 
C3 levels (94.1 mg/dL; normal range, 90−180 mg/dL), 
as well as seropositivity for anti-Sm and anti-RNP. 
Antibodies to double-stranded DNA, SS-A, SS-B, and 
cardiolipin were undetectable. The results of cere-
brospinal fluid analysis were unremarkable, with 
normal protein and glucose, no oligoclonal bands, 
and no pleocytosis (white blood cell count: 0/mm3).
Because of a high suspicion of NMO, the patient 
received high-dose intravenous methylprednisolone 
pulses (0.5 g/day) over 5 days, and then was main-
tained on prednisolone 20 mg orally per day. Her 
muscle power greatly improved, but urinary inconti-
nence was incompletely restored over a period of a 
month. For confirmation of NMO syndrome, NMO-IgG 
was assessed (Laboratoire de Neuropathologie of 
Hôpital Neurologique) and the result was positive. 
Overall, the patient met the definitive diagnostic 
criteria for NMO with the objective evidence of bilat-
eral ON with poor recovery, longitudinally extensive 
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Figure 1 (A) Sagittal T2-weighted magnetic resonance image (MRI) and (B) axial T2-weighted MRI with fat saturation 
demonstrate longitudinal myelitis. There are abnormal T2 bright signal intensities in the central region of the cord 
parenchyma (black arrowhead) from the C6 to T5 level (white arrow).
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myelitis, no involvement of other parts of the neu-
raxis, and positive NMO-IgG.
The patient developed acute myelitis again under 
the low-dosage prednisolone maintenance therapy. 
Therefore, aggressive treatment with an immuno-
suppressant was suggested. Because the laboratory 
data indicated systemic lupus erythematous (SLE) 
and there was an economic restriction on rituximab 
use, she started to receive monthly cyclophospha-
mide pulse therapy (0.75 g/m2). However, she had a 
urinary tract infection approximately 1−2 weeks after 
each monthly immunosuppressive therapy. Thus, 
after three times of monthly immunosuppressive 
treatments, she refused the following courses and 
only received prednisolone maintenance therapy. 
Approximately 2 months after stopping cyclophos-
phamide treatment, she was hospitalized several 
times for severe abdominal cramps or transverse 
myelitis and presented with low back pain, acute 
lower limb weakness, and urinary retention. Follow-
up spinal MRI approximately 1 year after the previous 
imaging (Figure 1) showed progressive long-segment 
myelopathy with cord atrophy from C6 to T10 and a 
patchy syrinx from T3 to T7 (Figure 2). The patient 
then received six courses of monthly cyclophospha-
mide pulse therapy (0.75 g/m2) and oral pred-
nisolone maintenance therapy with a starting dose 
of 20 mg/day. She was assessed monthly for clinical 
conditions and side effects. She had side effects of 
long-term steroid use, including a moon face, body 
weight gain, and a humped shoulder. After her gen-
eral condition stabilized, oral prednisolone was 
gradually tapered over approximately 4 months. 
Approximately 6 months after stopping monthly 
immunosuppressive therapy, no relapse symptoms 
were observed, and the long-term side effects of 
prednisolone had improved.
3.  Discussion
Neuromyelitis optica or Devic’s disease is a severe 
idiopathic immune-mediated inflammatory demyeli-
nating disease that predominantly involves the optic 
nerves and spinal cord.1−4 The cardinal clinical fea-
tures of the disorder are longitudinally extensive 
transverse myelitis and ON. These two clinical events 
can occur simultaneously or can be separated by 
many years. ON can be unilateral or bilateral and can 
occur before or after an attack of myelitis. More than 
90% of patients with NMO have repeated relapses 
(relapsing NMO) rather than monophasic disease. 
There are several differences in the characteristics 
and outcomes of patients with the monophasic and 
relapsing forms of NMO (Table 12).
It is important to differentiate between NMO and 
MS because the medical condition of NMO (especially 
relapsing NMO) is more severe than MS and the 
principles of treatment are different. A recent im-
portant finding was the discovery of a highly specific 
serum autoantibody marker, NMO-IgG,7,8 and the 
NMO-IgG test was incorporated into the updated 
2006 diagnostic criteria for NMO (Table 23). A com-
bination of clinical, laboratory, and neuroimaging 
features helps to discriminate NMO from MS and fa-
cilitates accurate prognosis and treatment (Table 
32,9−11). For example, oligoclonal bands are seen in 
85−90% of MS cases but in only 20−30% of NMO cases, 
and systemic autoimmune diseases are associated 
more with NMO than with MS. In our case, the diag-
nosis of NMO was made based on the clinical findings 
of first-ever ON and repeated transverse myelitis 
with contiguous spinal cord lesions extending over 
three or more vertebral segments on MRI. The bio-
logical data showed negative oligoclonal bands in 
cerebrospinal fluid and seropositive NMO-IgG. 
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Figure 2 (A) Sagittal T1-weighted magnetic resonance image (MRI) and (B) sagittal T2-weighted MRI of the cervical spine 
demonstrate radiographic progressive long segment myelopathy with atrophic changes in the cord from the C6 to T10 level 
(black arrow). There are small intramedullary T2 hyperintensities from T3 to T7 (white arrow), suggesting syrinx formation.
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Furthermore, an association with SLE was suspected 
because of a raised ANA titer (640×) and seropositivity 
for anti-Sm.
The NMO-IgG autoantibody test is very helpful for 
confirmation of NMO because of its high specificity 
(91%; 85−99%) and sensitivity (73%; 58−76%), and 
very little NMO-IgG autoantibody in MS.7,12 Its tar-
get antigen is the AQP4 water-pump channel, which 
is an integral protein of astrocytic plasma mem-
branes and is highly concentrated in the astrocyte 
foot processes.7,8 The distribution of AQP4-rich areas 
in the central nervous system, especially in the cen-
tral part of the spinal cord, hypothalamus, periv-
entricular area and periaqueductal areas, is highly 
compatible with that of NMO lesions.13−15 Spinal cord 
histopathology in NMO features the loss of AQP4 in 
acute inflammatory lesions surrounding immunoglob-
ulin and complement-deposited hyalinized small 
vessels.8,15 These changes suggest that autoimmu-
nity to AQP4 is involved in a humorally-mediated 
microangiopathy leading to spinal cord lesions in 
NMO. However, it is still unclear whether NMO-IgG 
is simply a valuable biomarker for NMO disease or 
if it is an autoantibody causing the damage. Recent 
studies on a new assay for anti-AQP4 antibody have 
demonstrated a high sensitivity of 91% and specificity 
of 100% for NMO.8,12,16 High anti-AQP4 antibody tit-
ers are associated with complete blindness and are 
positively correlated with the lengths of spinal cord 
lesions on MRI. Anti-AQP4 antibody titers decrease 
after high-dose methylprednisolone, and follow-up 
shows low anti-AQP4 antibody titers in relapse-free 
periods under immunosuppressive treatment.
Patients with myelitis should have a cervical and 
thoracic spinal cord MRI scan with intravenous gado-
linium administration to determine whether there 
is a longitudinally extensive cord lesion, which is the 
second major supportive diagnostic criterion for 
NMO.3 A radiological feature of NMO is a longitudi-
nally extensive cord lesion, often extending over 
three or more spinal segments, but MS involves fewer 
than two spinal segments.6,14,17 In our patient, MRI 
demonstrated an increased signal intensity with a 
central location of the cord from C6 to T5 on T2-
weighted images and a radiographic progression of 
longitudinal myelitis with cord atrophy from the 
C6 to T10 level and a patchy syrinx from the T3 to 
T7 level, which is consistent with the radiographic 
diagnostic criteria for NMO.
We still could not determine whether this case 
was NMO disease associated with a raised ANA titer 
and positive anti-Sm or NMO syndrome in unam-
biguous SLE. The patient’s biological data for ex-
amination of autoimmune disease was remarkable 
because of a raised ANA titer of 1:640 dilution, and 
seropositivity for anti-RNP and anti-Sm. Anti-Sm and 
anti-RNP have a high specificity (specificity > 90%) 
for SLE. Positive auto-antibodies have been reported 
in more than 50% of NMO patients. This can give 
rise to diagnostic difficulties. Several studies have 
recognized that both systemic autoimmune dis-
eases (e.g., SLE, Sjögren’s syndrome, and autoim-
mune thyroid disease) and positive serological test 
results may occur in conjunction with NMO.6





 At least 2 of the 3 supportive criteria
 1.  Contiguous spinal cord MRI lesion extends ≥ 3 
vertebral segments
 2.  Brain MRI does not meet diagnostic criteria for 
multiple sclerosis
 3. NMO-seropositive status 
NMO = neuromyelitis optica; MRI = magnetic resonance imaging.
Table 1 Characteristics of monophasic and relapsing neuromyelitis optica2
 Monophasic Relapsing
Frequency (%) Less common (20) More common (80)
Age of onset (yr; median) 29  39
Sex ratio of females (%) 50  80−90
History of autoimmune disease Uncommon  Approximately 50%
ON or myelitis (%) 48  90
Bilateral ON (%) 17  8
Simultaneous ON + myelitis (%) 31  0
Severity at nadir More severe Less severe
Respiratory failure Rare Approximately 1/3
5-yr mortality rate (%)  10  32
Recovery Good Fair
ON = optic neuritis.
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Table 3 Biological characteristics of multiple sclerosis (MS) and neuromyelitis optica(NMO)2,9−11
 MS NMO
Cerebral spinal fluid
 Pleocytosis Usually a normal cell count or modest  Relevant in acute attacks (> 50 cells/mm3),
  pleocytosis (< 50 cells/mm3) with a  and sometimes dominated by neutrophils
  predominance of lymphocytes  (high specificity > 95%, low sensitivity < 30%)
 Oligoclonal bands (%) 85−90 20−30
Serum
 Anti-nuclear Abs (%) 20−30  > 50
 Other auto-Abs (systemic Rare Frequent
  autoimmune disease)
 NMO-IgG Absent High sensitivity (73%)
  High specificity (91%)
Abs = antibodies; NMO-IgG = neuromyelitis optica-immunoglobulin G.
The treatment of NMO involves therapies to re-
verse recent symptoms and prevent future relapses. 
In the acute phase, methylprednisolone pulse ther-
apy is the first-line treatment.18,19 When clinical 
symptoms improve, a gradual taper of oral pred-
nisolone over several months is suggested to prevent 
complications and recurrence. If there is a bad re-
sponse to methylprednisolone or prednisolone, in-
travenous immune globulin and plasmapheresis are 
prescribed. In our patient, intravenous high-dose 
methylprednisolone (500 mg per day) was prescribed 
at the acute phase, and this resulted in relief from 
paraplegia, back pain, and abdominal cramps.
In the relapse phase, it is important to stabilize 
clinical conditions and prevent relapses. Azathioprine 
(2.5−3 mg/kg/daily) is the first choice of immuno-
suppressant for relapses of NMO.20 In patients who 
have bad responses to azathioprine, rituximab can 
be a substitute for azathioprine for relapses of NMO.21 
Rituximab is a B-cell-depleting monoclonal antibody 
against the protein CD20. NMO with unambiguous 
SLE was diagnosed in our patient. Therefore, cyclo-
phosphamide was recommended for this patient 
instead of azathioprine. Cyclophosphamide is a ni-
trogen mustard alkylating agent and is used to treat 
various types of cancer, autoimmune disorders, and 
connective tissue disorders. The patient steadily im-
proved under the first three courses of monthly cy-
clophosphamide pulse therapy (500 mg per month), 
and she had relapses of myelitis after discontinuing 
immunosuppressant therapy due to app rehension 
of the side effects of the immuno suppressant. She 
then completed six courses of monthly immuno-
suppressant treatments and was maintained on 
oral prednisolone with the dose ranging from 5 mg 
to 20 mg. Approximately 6 months after stopping 
monthly immunosuppressant therapy, no relapse 
symptoms were observed, and the side effects of 
prednisolone had improved. Thus, cyclophosphamide 
is another choice for NMO patients (especially NMO 
with autoimmune disorder or connective tissue 
disorder).
In conclusion, rapid diagnosis and early initiation 
of aggressive immunosuppressive treatment are 
essential in most NMO cases. Although NMO is rare in 
childhood, cases with ON, especially bilateral simul-
taneous ON or sequential ON in rapid succession, 
as well as longitudinally extensive myelitis should be 
evaluated in detail, and the possibility of NMO should 
be taken into account in the differential diagnosis.
References
1. Cree BA, Goodin DS, Hauser SL. Neuromyelitis optica. 
Semin Neurol 2002;22:105−22.
2. Wingerchuk DM, Hogancamp WF, O’Brien PC, et al. The 
clinical course of neuromyelitis optica (Devic’s syndrome). 
Neurology 1999;53:1107−14.
3. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, 
Weinshenker BG. Revised diagnostic criteria for neuromye-
litis optica. Neurology 2006;66:1485−9.
4. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. 
Curr Treat Options Neurol 2008;10:55−66.
5. Kira JI. Multiple sclerosis in the Japanese population. Lancet 
Neurol 2003;2:117−27.
6. Jacob A, Boggild M. Neuromyelitis optica. Pract Neurol 2006;
6:180−4.
7. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum 
autoantibody marker of neuromyelitisoptica: distinction 
from multiple sclerosis. Lancet 2004;364:2106−12.
8. Takahashi T, Fujihara K, Nakashima I, et al. Anti-
aquaporin-4 antibody is involved in the pathogenesis of 
NMO: a study on antibody titre. Brain 2007;130:1235−43.
9. Wingerchuk DM. Neuromyelitis optica. Int MS J 2006;13:42−50.
10. Wingerchuk DM. Diagnosis and treatment of neuromyelitis 
optica. Neurologist 2007;13:2−11.
11. Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple 
sclerosis in children: clinical diagnosis, therapeutic strate-
gies, and future directions. Lancet Neurol 2007;6:887−902.
12. Jarius S, Paul F, Franciotta D, et al. Mechanism of disease: 
aquaporin-4 antibodies in neuromyelitis optica. Nat Clin 
Pract Neurol 2008;4:202−14.
352 W.C. Chia et al
13. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. 
Intractable hiccup and nausea with periaqueductal lesions 
in neuromyelitis optica. Neurology 2005;65:1479−82.
14. Nakashima I, Fujihara K, Miyazawa I, et al. Clinical and MRI 
features of Japanese patients with multiple sclerosis posi-
tive for NMO-IgG. J Neurol Neurosurg Psychiatry 2006;77:
1073−5.
15. Pittock SJ, Wewinshenker BG, Lucchinetti CF, Wingerchuk DM, 
Corboy JR, Lennon VA. Neuromyelitis optica brain lesions 
localized at sites of high aquaporin 4 expression. Arch Neurol 
2006;63:964−8.
16. Waters P, Vincent A. Detection of anti-aquaporin-4 antibod-
ies in neuromyelitis optica: current status of the assays. Int 
MS J 2008;15:99−105.
17. Filippi M, Rocca MA, Moiola L, et al. MRI and magnetization 
transfer imaging changes in the brain and cervical cord of 
patients with Devic’s neuromyelitis optica. Neurology 1999;
53:1705−10.
18. Watanabe S, Nakashima I, Misu T, Shiga Y, Fugihara K, 
Itoyama Y. Therapeutic efficacy of plasma exchange in 
NMO-IgG positive patients with neuromyelitis optica. Mult 
Scler 2007;13:128−32.
19. Weinshenker BG, O’Brien PC, Petterson TM, et al. A ran-
domized trial of plasma exchange in acute inflammatory cen-
tral nervous system inflammatory demyelinating diseases. 
Ann Neurol 1999;46:878−86.
20. Cree BA, Lamb S, Morgan A, et al. An open label study of 
the effects of rituximab in neuromyelitis optica. Neurology 
2005;64:1270−2.
21. Jacob A, Weinshenker BG, Violich I, et al. Treatment of 
neuromyelitis optica with rituximab: retrospective analysis 
of 25 patients. Arch Neurol 2008;65:1443−8.
